相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Trabectedin for recurrent WHO grade 2 or 3 meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG)
Matthias Preusser et al.
NEURO-ONCOLOGY (2022)
Implementation of TERT promoter mutations improve prognostication of the WHO classification in meningioma
Christian Mirian et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2022)
Prognostic impact of genetic alterations and methylation classes in meningioma
Anna S. Berghoff et al.
BRAIN PATHOLOGY (2022)
Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results
Wenya Linda Bi et al.
NEURO-ONCOLOGY (2022)
Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas
Priscilla K. Brastianos et al.
NATURE COMMUNICATIONS (2022)
Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated
Sybren L. N. Maas et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Sporadic multiple meningiomas harbor distinct driver mutations
Tareq A. Juratli et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2021)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2021)
Clinical significance of checkpoint regulator Programmed death ligand-1 (PD-L1) expression in meningioma: review of the current status
Shirin Karimi et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Loss of H3K27me3 in meningiomas
Farshad Nassiri et al.
NEURO-ONCOLOGY (2021)
Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas
Jacky Yeung et al.
NEURO-ONCOLOGY (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
EANO guideline on the diagnosis and management of meningiomas
Roland Goldbrunner et al.
NEURO-ONCOLOGY (2021)
Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial
Thomas Graillon et al.
CLINICAL CANCER RESEARCH (2020)
Poor prognosis associated with TERT gene alterations in meningioma is independent of the WHO classification: an individual patient data meta-analysis
Christian Mirian et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2020)
Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.
Priscilla Kaliopi Brastianos et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Programmed death ligand-1 (PD-L1) expression in meningioma; prognostic significance and its association with hypoxia and NFKB2 expression
Shirin Karimi et al.
SCIENTIFIC REPORTS (2020)
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic
Erik A. Williams et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2020)
Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group
Raymond Y. Huang et al.
NEURO-ONCOLOGY (2019)
Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas
Carmen Rapp et al.
CLINICAL CANCER RESEARCH (2019)
Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas
Shuyu Hao et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management
Farshad Nassiri et al.
NEURO-ONCOLOGY (2019)
Intraventricular meningiomas frequently harbor NF2 mutations but lack common genetic alterations in TRAF7, AKT1, SMO, KLF4, PIK3CA, and TERT
Gerhard Jungwirth et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2019)
Identification of PD-L2, B7-H3 and CTLA-4 immune checkpoint proteins in genetic subtypes of meningioma
Dustin T. Proctor et al.
ONCOIMMUNOLOGY (2019)
Genomic Analysis of Posterior Fossa Meningioma Demonstrates Frequent AKT1 E17K Mutations in Foramen Magnum Meningiomas
Sally R. Williams et al.
JOURNAL OF NEUROLOGICAL SURGERY PART B-SKULL BASE (2019)
Programmed death ligand 1 expression and tumor infiltrating lymphocytes in neurofibromatosis type 1 and 2 associated tumors
Shiyang Wang et al.
JOURNAL OF NEURO-ONCOLOGY (2018)
Management of multiple meningiomas
Georgios Tsermoulas et al.
JOURNAL OF NEUROSURGERY (2018)
Advances in meningioma genetics: novel therapeutic opportunities
Matthias Preusser et al.
NATURE REVIEWS NEUROLOGY (2018)
DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome
Tareq A. Juratli et al.
ACTA NEUROPATHOLOGICA (2018)
Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade
Ian E. Dunn et al.
JCO PRECISION ONCOLOGY (2018)
Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine
Laetitia Nebot-Bral et al.
EUROPEAN JOURNAL OF CANCER (2017)
Targeted sequencing of SMO and AKT1 in anterior skull base meningiomas
Matthew R. Strickland et al.
JOURNAL OF NEUROSURGERY (2017)
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis
Felix Sahm et al.
LANCET ONCOLOGY (2017)
Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence
Uemmueguelsuem Yesiloez et al.
NEURO-ONCOLOGY (2017)
BAP1 mutations in high-grade meningioma: implications for patient care
Ganesh M. Shankar et al.
NEURO-ONCOLOGY (2017)
Integrated genomic analyses of de novo pathways underlying atypical meningiomas
Akdes Serin Harmanci et al.
NATURE COMMUNICATIONS (2017)
Genomic landscape of high-grade meningiomas
Wenya Linda Bi et al.
NPJ GENOMIC MEDICINE (2017)
Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma
Adriana Olar et al.
ACTA NEUROPATHOLOGICA (2017)
Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)
Elena Mazza et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature
Rachael A. Vaubel et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2016)
TERT Promoter Mutations and Risk of Recurrence in Meningioma
Felix Sahm et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma
Julia Furtner et al.
NEURO-ONCOLOGY (2016)
Role of Merlin/NF2 inactivation in tumor biology
A. M. Petrilli et al.
ONCOGENE (2016)
TERT Promoter Mutations and Risk of Recurrence in Meningioma
Felix Sahm et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma
Kent C. Shih et al.
JOURNAL OF NEURO-ONCOLOGY (2016)
Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas
Victoria E. Clarke et al.
NATURE GENETICS (2016)
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma
Malak Abedalthagafi et al.
NEURO-ONCOLOGY (2016)
Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005
Yongli Ji et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review
Leland Rogers et al.
JOURNAL OF NEUROSURGERY (2015)
Descriptive epidemiology of World Health Organization grades II and III intracranial meningiomas in the United States
Varun R. Kshettry et al.
NEURO-ONCOLOGY (2015)
Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma
Ziming Du et al.
ONCOTARGET (2015)
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma
Thomas J. Kaley et al.
NEURO-ONCOLOGY (2015)
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma
Andrew D. Norden et al.
NEUROLOGY (2015)
Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy
Marta Simo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Germline SMARCE1 mutations predispose to both spinal and cranial clear cell meningiomas
Miriam J. Smith et al.
JOURNAL OF PATHOLOGY (2014)
Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma: a RANO review
Thomas Kaley et al.
NEURO-ONCOLOGY (2014)
Immunohistochemical analysis of cyclooxygenase-2 and brain fatty acid binding protein expression in grades I-II meningiomas: Correlation with tumor grade and clinical outcome after radiotherapy
Hyun-Cheol Kang et al.
NEUROPATHOLOGY (2014)
Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations
David E. Reuss et al.
ACTA NEUROPATHOLOGICA (2013)
Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas
Miriam J. Smith et al.
NATURE GENETICS (2013)
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations
Priscilla K. Brastianos et al.
NATURE GENETICS (2013)
Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO
Victoria E. Clark et al.
SCIENCE (2013)
Trabectedin Has Promising Antineoplastic Activity in High-Grade Meningioma
Matthias Preusser et al.
CANCER (2012)
Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma
Marc C. Chamberlain
JOURNAL OF NEURO-ONCOLOGY (2012)
Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series
Emil Lou et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Atypical and anaplastic meningiomas treated with bevacizumab
Lakshmi Nayak et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Regulation of mTOR Complex 2 Signaling in Neurofibromatosis 2-Deficient Target Cell Types
Marianne F. James et al.
MOLECULAR CANCER RESEARCH (2012)
Analysis of transforming growth factor β receptor expression and signaling in higher grade meningiomas
Mahlon D. Johnson et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
The Hedgehog's tale: developing strategies for targeting cancer
Jessica M. Y. Ng et al.
NATURE REVIEWS CANCER (2011)
Genomic Profiling Reveals Alternative Genetic Pathways of Meningioma Malignant Progression Dependent on the Underlying NF2 Status
Stephane Goutagny et al.
CLINICAL CANCER RESEARCH (2010)
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma
Andrew D. Norden et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Pathological classification and molecular genetics of meningiomas
Christian Mawrin et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas
Yiping Shen et al.
BMC MEDICAL GENOMICS (2009)
Bone Morphogenetic Protein 4 and Its Receptors Are Expressed in the Leptomeninges and Meningiomas and Signal via the Smad Pathway
Mahlon D. Johnson et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2009)
NF2/Merlin Is a Novel Negative Regulator of mTOR Complex 1, and Activation of mTORC1 Is Associated with Meningioma and Schwannoma Growth
Marianne F. James et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2009)
Interferon-α for Recurrent World Health Organization Grade 1 Intracranial Meningiomas
Marc C. Chamberlain et al.
CANCER (2008)
Correspondence of tumor localization with tumor recurrence and cytogenetic progression in meningiomas
Ralf Ketter et al.
NEUROSURGERY (2008)
Recurrent meningioma - Salvage therapy with long-acting somatostatin analogue
Marc C. Chamberlain et al.
NEUROLOGY (2007)
Meningothelioma as the predominant histological subtype of midline skull base and spinal meningioma
JH Lee et al.
JOURNAL OF NEUROSURGERY (2006)
Salvage chemotherapy with CPT-11 for recurrent meningioma
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
NF2 mutations in secretory and other rare variants of meningiomas
C Hartmann et al.
BRAIN PATHOLOGY (2006)
Temozolomide for treatment-resistant recurrent meningioma
MC Chamberlain et al.
NEUROLOGY (2004)
NF2 status of meningiomas is associated with tumour localization and histology
J Kros et al.
JOURNAL OF PATHOLOGY (2001)
Meningioma: a cytogenetic model of a complex benign human tumor, including data on 394 karyotyped cases
KD Zang
CYTOGENETICS AND CELL GENETICS (2001)
分享论文
